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A new series of 5-(1H-benzo[d] imidazol-2-yl) methyl)-3-(3,5-dimethyl-4-isoxazolyl)-2-aryl-thiazolidin-4-ones 4 have 
been accomplished by a simple synthetic protocol. The reaction of 4-benzalamino-3,5-dimethylisoxazoles 3 with mercapto 
succinic acid furnishes 2-(3-(3,5-dimethyl-4-isoxazolyl)-4-oxo-2-aryl thiazolidin-5-yl) acetic acids 3, which are then 
cyclized to the title compounds viz., isoxazolyl thiazolyl benzimidazoles 4 on treatment with 1,2-phenylene diamines. The 
title compounds 4 have been screened for their anti-inflammatory and analgesic activity. 
Keywords: Isoxazolyl thiazolyl benzimidazoles, cyclocondensation, anti-inflammatory activity, analgesic activity 
Benzimidazole is an important nucleus that has been 
extensively used in medicinal chemistry, notable 
examples being the antihistaminic asterizole and the 
antiulcerative omeprazole
1
. Benzimidazoles are also 
known for their anti-inflammatory
2
, antibiotic
3
, 
antihelmintic
4
, anticancer
5
, and antiviral activities
6
. 
Thiazolidinones and their derivatives has received 
much attention due to wide range of biological 
activities such as antioxidant
7
, anti-inflammatory and 
analgesic
8
, antitumor
9
, antitubercular
10
, arthritis
11
, 
antimicrobial
12
, antidiabetic
13
 activity. Thiazolidinone 
derivatives have been found to exhibit NSAIDs activity 
through the selective COX-2 inhibitory mechanism
14
, 
and were found to be more potent than reference drugs. 
A large number of isoxazole derivatives exhibited 
analgesic and anti-inflammatory
15
, anti-convulsant
16
, 
anticancer
17
, antibacterial
18
 and antitubercular
19
 
activities.  
Molecular hybridization is a relatively new concept 
in the field of drug design, and development involving 
the fusion of two or more pharmocophoric submits 
which have an inhibitory effect against the target 
disease. The newly designed structure can lead to 
compounds having improved affinity and effects  
than the parent compounds with reduced side effects, 
while retaining the desired characteristics of  
original template
20-22
. Prompted by these reports, the 
researchers are interested to construct isoxazolyl 
thiazolyl benzimidazole hybrids by utilizing a simple 
synthetic protocol to evaluate the anti-inflammatory 
and analgesic activities of these compounds. Synthesis 
and anti-inflammatory and analgesic activity of 5-(1H-
benzo[d] imidazol-2-yl) methyl)-3-(3,5-dimethyl-4-
isoxazolyl)-2-aryl-thiazolidin-4-ones have been reported. 
 
Results and Discussion 
 
Chemistry 
The synthesis of title compounds (4) was 
accomplished by the synthetic sequence shown in the 
Scheme I. The reaction of 4-benzalamino-3,5-dimethyl 
isoxazoles (2)
23
 with mercapto succinic acid in 
presence of traces of anhy. ZnCl2 in dioxane afforded 
the corresponding 2-(3-(3,5-dimethyl-4-isoxazolyl)-4-
oxo-2-aryl thiazolidin-5-yl) acetic acids (3) by 
cyclocondensation. Isoxazolyl thiazolidin-4-ones (3) 
possessing acetic acid side chain, on treatment with 
1,2-phenylene diamines in pyridine underwent 
cyclocondensation to furnish the title compounds viz., 
5-(1H-benzo[d] imidazol-2-yl) methyl)-3-(3,5-
dimethyl-4-isoxazolyl)-2-aryl-thiazolidin-4-ones (4). 
The structures of the newly synthesized compounds 
3 and 4 were established by spectral and analytical data 
(Table I and Table II). 
IR spectra of isoxazolyl acetic acids (3) exhibited 
strong absorption bands at 1680 and 1700 cm
−1 
due to 
carbonyl group and 3350 cm
−1
 due to OH group 
stretching vibrations respectively. 
1
H NMR spectra of 
(3) displayed two distinct signals as a triplet at δ 4.5 
and a doublet at δ 3.2 due to COCHS and CH2 protons 
respectively. The lone -N-CH-Ar proton resonated as a 
singlet at δ 5.6, whereas -COOH proton appeared as a 
broad singlet at δ 10.5,  which is  D2O  exchangeable.  
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The mass spectrum of (3a) exhibited the molecular ion 
[M+H]
+ 
peak at m/z 333 confirming cyclization. IR 
spectra of isoxazolyl thiazolyl benzimidazoles (4) 
exhibited strong absorption bands at 1680 and 3295 
cm
−1
 due to carbonyl and NH functional groups 
stretching vibrations respectively. The absence of 1700  
 
and 3350 cm
−1
 absorption bands in the IR spectra of (4) 
clearly confirms the cyclization, which are present  
in its precursor due to C=O and OH groups 
respectively.(3).
 1
H NMR spectra of (4) showed a 
characteristic singlet at δ 9.0, which is D2O 
exchangeable due to benzimidazole NH proton 
Table I — Anti-inflammatory activity of compounds 4a-j 
Compd Volume of edemab (% inhibition) 
1 h 2 h 3 h 4 h 
4a 72.2 ± 3.6 84.1 ± 8.4 88.2 ± 4.6 91.0 ± 6.2 
4b 52.1 ± 3.9 66.5 ± 7.2
c 71.2 ± 5.4c 78.6 ± 3.4 
4c 50.8 ± 5.2 69.8 ± 4.5
c 74.6 ± 5.7c 86.4 ± 6.2 
4d 50.1 ± 3.8 81.7 ± 6.9 81.1 ± 5.4 76.6 ± 3.2
c 
4e 52.1 ± 4.4 56.1 ± 5.7
c 61.8 ± 3.7c 77.1 ± 2.8 
4f 60.1 ± 7.9 68.0 ± 4.5
c 67.4 ± 7.2c 72.0 ± 7.4c 
4g 58.2 ± 6.1 71.2 ± 2.6
c 78.6 ± 3.6c 77.1 ± 7.6c 
4h 51.4 ± 7.1 59.6 ± 7.3 61.2 ± 4.2
c 66.5 ± 4.8c 
4i 67.2 ± 7.5 81.5 ± 7.6 80.9 ± 3.4 81.2 ± 6.4 
4j 70.2 ± 3.5 73.5 ± 2.6 81.2 ± 3.5 85.5 ± 6.0 
Control 59.2 ± 6.4 89.4 ± 7.3 96.2 ± 2.5 91.2 ± 2.3 
Indomethacin 48.8 ± 5.0 43.6 ± 4.9 46.4 ± 4.3 47.8 ± 5.4 
a Dose levels, PO: test compound(10 mg/kg b.wt) Indomethacin  
(10 mg/kg b.wt) 
b Values are expected as means ± S.E. (number of rats N=6 rats) 
c Statistically significant compared to respective control values, 
P<0.05 (Dunnett’s test) 
 
 
 
Scheme I 
 
Table II — Analgesic activity of compounds 4a-j 
Compd 
Reaction time (sec) (%inhibition) 
0 h 1 h 2 h 
4a 15.2 ± 1.86 16.5 ± 1.75 16.6 ± 2.31 
4b 18.6 ± 2.30 23.6 ± 2.84
c 25.3 ± 2.82c 
4c 15.6 ± 1.92 25.6 ± 2.82
c 21.8 ± 1.02c 
4d 19.9 ± 2.69 18.2 ± 2.81
c 20.1 ± 2.68 
4e 17.9 ±2.53 23.5 ± 2.82
c 11.2 ± 1.82c 
4f 15.9 ± 1.92 20.9 ± 1.23
c 17.2 ± 1.91c 
4g 17.5 ± 2.04 22.7 ± 2.61
c 22.8 ± 2.38c 
4h 15.4 ±1.56 20.1 ± 2.21 20.9 ± 2.18
c 
4i 16.9 ± 2.63 14.7 ± 1.23 22.5 ± 0.83
c 
4j 20.1 ± 1.80 23.6 ± 1.50 25.5 ± 0.75 
Control 16.4 ± 0.65 16.2 ± 0.85 16.4 ± 1.20 
Indomethacin 17.3 ± 0.80 21.8 ± 0.34 22.4 ± 0.30 
a Dose levels, PO: test compound(10 mg/kg b.wt) Indomethacin 
(10 mg/kg b.wt) 
b Values are expected as means ± S.E(number of rats N=6 rats) 
c Statistically significant compared to respective control values, 
P<0.05(Dunnett’s test) 
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confirming cyclization. The mass spectrum of (4a) 
displayed a molecular ion [M+H]
+
 peak at m/z 405. 
Elemental analyses are also confirmed with the 
structures proposed for compounds 3 and 4. 
 
Anti-inflammatory activity 
The anti-inflammatory activity of newly synthesized 
compounds 4a-j was evaluated by Carrageenan-induced 
paw edema method in rats
24
 using Indomethacin as a 
standard drug. The anti-inflammatory activity data 
(Table I) indicated that all the test compounds caused 
significant inhibition of paw edema response. 
Compounds 4b, 4e, 4f, and 4h caused significant 
decrease in paw edema after 2,3, and 4 h drug 
administration by causing inhibition to the extent of 
25%, 37%, 29%, and 36% respectively, while 
compounds 4c and 4g gave their response after 2 h of 
administration and continued to the third hour by 
causing inhibition to the extent of 22%, and 20% 
respectively. On the other hand, compounds 4a, 4d, 
4i, and 4j were inactive towards Carrageenan-induced 
paw edema causing inhibition only to the extent of 
8%, 16%, 15%, and 17% respectively in comparison 
with reference drug Indomethacin (inhibition 17%). 
Thus compounds 4b, 4e, 4f, and 4h exhibited good 
anti-inflammatory activity. Among all the test 
compounds, it is important to note that compounds 4e 
and 4h showed best anti-inflammatory activity. 
 
Analgesic activity 
The analgesic activity of newly synthesized 
compounds 4a-j were evaluated by hot plate method
25
 
using Indomethacin as a reference drug. Methods of 
statistical analysis were done according to Armitage 
et al.
26
 The analgesic activity was measured at 0, 1 
and 2 h time intervals after pain induction. The 
analgesic activity data (Table II) indicated that the test 
compounds exhibited moderate to good analgesic 
activity .Compounds 4b, 4c, 4e, 4g, and 4j showed 
significant analgesic activity by causing inhibition  
to the extent of 23%, 25%, 23%, 22%, and 23% 
respectively compared to reference drug Indomethacin 
(inhibition 21%), after 1 h post-administration and 
25%, 21% 11%, 22%, and 25% respectively after  
2 h post-administration. Compounds 4d, 4f, and 4g 
exhibited slightly less activity than Indomethacin 
(inhibition 21%) by causing inhibition to the extent of 
18%, 20%, and 22% respectively, whereas compounds 
4a and 4i have least analgesic activity with inhibition 
of 16% and 14% respectively. Thus compounds 4b, 
4c, 4e, and 4j have good analgesic activity. Among all 
the test compounds it is important to note that 
compounds 4b and 4j showed good analgesic activity. 
 
Experimental Section 
All the melting points were determined on a  
Cintex melting point apparatus and are uncorrected. 
Analytical TLC was performed on a Merck precoated 
60 F254 silica gel plates. Visualization was carried out 
by exposure to iodine vapour. IR spectra (KBr pellet) 
were recorded on a Perkin-Elmer BX series FT-IR 
spectrometer. 
1
H NMR spectra were recorded on a 
Brucker 300 MHz spectrometer using TMS as internal 
standard (Chemical shift values are given in  ppm). 
Mass spectra were scanned on a Agilent LC-MSD 
mass spectrometer. C, H, N analyses were carried  
out on a Carlo Erba 106 and Perkin-Elmer model 
analyzers. 3,5-Dimethyl-4-aminoisoxazole was purchased 
from Sigma-Aldrich chemicals, USA. 
 
General procedure for the synthesis of 2-(3-(3,5-
dimethyl-4-isoxazolyl)-4-oxo-2-aryl thiazolidin-5-
yl) acetic acids, 3 
4-Benzalamino-3,5-dimethylisoxazole (2) (0.01 
mol), mercapto succinic acid (0.01 mol) were taken in 
dioxane (15 mL). To this traces of anhyd. ZnCl2 was 
added and the contents are refluxed in a Dean-Stark 
apparatus for 6 h. The reaction mixture was cooled 
and poured on to ice-cold water. The separated 
product was filtered and recrystallized from ethanol. 
3a: Yield 80%. m.p. 90-92°C. IR (KBr): 1680 
(C=O), 1700 (C=O), 3355 (OH) cm
−1
; 
1
H NMR (300 
MHz, CDCl3): δ 2.2 (s, 3H, CH3), 2.4 (s, 3H, CH3), 
3.2 (d, 2H, CH2), 4.5 (t, 1H, COCHS), 5.6 (s, 1H,  
N-CH-Ar), 7.2-7.6 (m, 5H, Ar-H), 10.8 (bs, 1H, 
COOH, D2O exchangeable); ESI-MS: m/z 333 
[M+H]
+
. Anal. Calcd. for C16H16N2O4S; C, 57.83; H, 
4.81; N, 8.43. Found: C, 57.86; H, 4.85; N, 8.40%. 
3b: Yield 75%. m.p. 100-102°C. IR (KBr): 1675 
(C=O), 1700 (C=O), 3350 (OH) cm
−1
; 
1
H NMR (300 
MHz, CDCl3): δ 2.2 (s, 3H, CH3), 2.3 (s, 3H, CH3), 
2.5 (s, 3H, CH3), 3.3 (d, 2H, CH2), 4.4 (t, 1H, 
COCHS), 5.7 (s, 1H, N-CH-Ar), 7.1-7.3 (d, 2H,  
Ar-H), 7.4-7.6 (d, 2H, Ar-H), 10.8 (bs, 1H, COOH, 
D2O exchangeable); ESI-MS: m/z 347 [M+H]
+
. Anal. 
Calcd. for C17H18N2O4S; C, 58.95; H, 5.20; N, 8.09. 
Found: C, 58.92, H, 5.23, N, 8.07%. 
3c: Yield 70% m.p. 96-98°C. IR (KBr): 1670 
(C=O), 1705 (C=O), 3340 (OH) cm
−1
; 
1
H NMR (300 
MHz, CDCl3): δ 2.2 (s, 3H, CH3), 2.3 (s, 3H, CH3), 
3.3 (d, 2H, CH2), 3.8 (s, 3H, OCH3), 4.5 (t, 1H, 
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COCHS), 5.5 (s, 1H, N-CH-Ar), 7.0-7.2 (d, 2H,  
Ar-H), 7.3-7.4 (d, 2H, Ar-H), 10.5 (bs, 1H, COOH, 
D2O exchangeable); ESI-MS: m/z 363 [M+H]
+
. Anal. 
Calcd. for C17H18N2O5S C, 56.35; H, 4.97; N, 7.73. 
Found: C, 56.38, H, 4.94, N, 7.72%. 
3d: Yield 75%. m.p.135-37°C. IR (KBr): 1670 
(C=O), 1700 (C=O), 3350 (OH) cm
−1
; 
1
H NMR (300 
MHz, CDCl3): δ 2.1 (s, 3H, CH3), 2.2 (s, 3H, CH3), 
3.3 (d, 2H, CH2), 4.5 (t, 1H, COCHS), 5.6 (s, 1H,  
N-CH-Ar), 7.2-7.7 (m, 4H, Ar-H), 10.7 (bs, 1H, 
COOH, D2O exchangeable); ESI-MS: m/z 367 
[M+H]
+
. Anal. Calcd. for C16H15N2O4SCl: C, 52.45; 
H, 4.09; N, 7.65. Found: C, 52.48, H, 4.11, N, 7.62%. 
3e: Yield 65%. m.p. 140-42°C. IR (KBr): 1675 
(C=O), 1700 (C=O), 3345 (OH) cm
−1
; 
1
H NMR (300 
MHz, CDCl3): δ 2.0 (s, 3H, CH3), 2.2 (s, 3H, CH3), 
3.5 (d, 2H, CH2), 4.6 (t, 1H, COCHS), 5.5 (s, 1H,  
N-CH-Ar), 7.2-7.6 (m, 4H, Ar-H), 10.8 (bs, 1H, 
COOH, D2O exchangeable); ESI-MS: m/z 367 
[M+H]
+
. Anal. Calcd. for C16H15N2O4SCl: C, 52.45; 
H, 4.09; N, 7.65. Found: C, 52.42, H, 4.06, N, 7.68%. 
3f: Yield 65%. m.p. 111-13°C. IR (KBR): 1670 
(C=O), 1705 (C=O), 3340 (OH) cm
−1
; 
1
H NMR (300 
MHz, CDCl3): δ 2.2 (s, 3H, CH3), 2.3 (s, 3H, CH3), 2.6 
(s, 3H, CH3), 3.4 (d, 2H, CH2), 4.5 (t, 1H, COCHS), 5.6 
(s, 1H, N-CH-Ar), 7.2-7.7 (m, 4H, Ar-H), 10.7 (bs, 1H, 
COOH, D2O exchangeable); ESI-MS: m/z 347 [M+H]
+
. 
Anal. Calcd. for C17H18N2O4S: C, 58.95; H, 5.20; N, 
8.09. Found: C, 58.98, H, 5.18, N, 8.11%. 
3g: Yield 72%. m.p. 120-22°C IR (KBr): 1665 
(C=O), 1695 (C=O), 3350 (OH) cm
−1
; 
1
H NMR (300 
MHz, CDCl3): δ 2.1 (s, 3H, CH3), 2.3 (s, 3H, CH3), 
3.3 (d, 2H, CH2), 3.8 (s, 3H, OCH3), 4.6 (t, 1H, 
COCHS), 5.5 (s, 1H, N-CH-Ar), 7.2-7.5 (m, 3H,  
Ar-H), 10.1 (bs, 1H, OH, D2O exchangeable), 10.9 
(bs, 1H, COOH, D2O exchangeable); ESI-MS: m/z 
379 [M+H]
+
. Anal. Calcd. for C17H18N2O6S: C, 53.96; 
H, 4.76; N, 7.40. Found: C, 53.99, H, 4.79, N, 7.43%. 
3h: Yield 73%. m.p. 127-29°C. IR (KBr): 1670 
(C=O), 1700 (C=O), 3340 (OH) cm
−1
; 
1
H NMR (300 
MHz, CDCl3): δ 2.2 (s, 3H, CH3), 2.3 (s, 3H, CH3), 3.3 
(d, 2H, CH2), 4.0 (s, 2H, -OCH2O), 4.6 (t, 1H, COCHS), 
5.6 (s, 1H, N-CH-Ar), 7.2-7.5 (m, 3H, Ar-H), 10.8 (bs, 
1H, OH, D2O exchangeable); ESI-MS: m/z 377 [M+H]
+
. 
Anal. Calcd. for C17H16N2O6S: C, 54.25; H, 4.25; N, 
7.44. Found: C, 54.22, H, 4.22, N, 7.48%. 
 
General procedure for the synthesis of 5-(1H-
benzo[d] imidazol-2-yl) methyl)-3-(3,5-dimethyl-4-
isoxazolyl)-2-aryl-thiazolidin-4-ones, 4 
Isoxazolyl thaizolyl acetic acids (3) (0.01 mmol) 
and 1,2-phenylene diamines (0.01 mmol) were 
dissolved in pyridine (15 mL), and the contents are 
refluxed for 5 h. After completion of the reaction  
(as indicated by TLC), the reaction mixture was 
cooled and poured over ice-cold water with stirring. 
The separated solid was filtered, washed with water 
dried and, recrystallized from methanol. 
4a: Yield 75%. m.p. 125-27°C. IR (KBr): 1680 
(C=O), 3285 (NH) cm
−1
; 
1
H NMR (300 MHz, 
CDCl3): δ 2.2 (s, 3H, CH3), 2.3 (s, 3H, CH3), 3.3  
(d, 2H, CH2), 4.5 (t, 1H, COCHS), 5.5 (s, 1H, N-CH-
Ar), 7.1-7.7 (m, 9H, Ar-H), 9.0 (bs, 1H, NH, D2O 
exchangeable); ESI-MS: m/z 405 [M+H]
+
. Anal. 
Calcd. for C22H20N4O2S: C, 65.34; H, 4.95; N, 13.86. 
Found: C, 65.30; H, 4.92; N, 13.85%. 
4b: Yield 70%. m.p. 134-36°C. IR (KBr): 1685 
(C=O), 3295 (NH) cm
−1
; 
1
H NMR (300 MHz, 
CDCl3): δ 2.1 (s, 3H, CH3), 2.3 (s, 3H, CH3), 2.5  
(s, 3H, CH3), 3.5 (d, 2H, CH2), 4.6 (t, 1H, COCHS), 
5.4 (s, 1H, N-CH-Ar), 7.0-7.8 (m, 8H, Ar-H), 9.5 (bs, 
1H, NH, D2O exchangeable); ESI-MS: m/z 419 
[M+H]
+
. Anal. Calcd. for C23H22N4O2S: C, 66.02; H, 
5.26; N, 13.39. Found: C, 66.05; H, 5.28; N, 13.37%. 
4c: Yield 70%. m.p. 150-52°C IR (KBr): 1665 
(C=O), 3275 (NH) cm
−1
; 
1
H NMR (300 MHz, 
CDCl3): δ 2.1 (s, 3H, CH3), 2.2 (s, 3H, CH3), 2.6 (s, 
3H, CH3), 3.4 (d, 2H, CH2), 4.5 (t, 1H, COCHS), 5.5 
(s, 1H, N-CH-Ar), 7.0-7.7 (m, 7H, Ar-H), 9.3 (bs, 1H, 
NH, D2O exchangeable); ESI-MS: m/z 464 [M+H]
+
. 
Anal. Calcd. for C23H21N5O4S: C, 59.61; H, 4.53; N, 
15.11. Found: C, 59.64; H, 4.56; N, 15.14%. 
4d: Yield 75%. m.p. 140-42°C. IR (KBr): 1670 
(C=O), 3300 (NH) cm
−1
; 
1
H NMR (300 MHz, 
CDCl3): δ 2.2 (s, 3H, CH3), 2.3 (s, 3H, CH3), 3.5 (d, 
2H, CH2), 3.7 (s, 3H, OCH3), 4.5 (t, 1H, COCHS), 5.4 
(s, 1H, N-CH-Ar), 7.1-7.8 (m, 8H, Ar-H), 9.5 (bs, 1H, 
NH, D2O exchangeable); ESI-MS: m/z 435 [M+H]
+
. 
Anal. Calcd. for C23H22N4O3S: C, 63.59; H, 5.06; N, 
12.90. Found: C, 63.56; H, 5.09; N, 12.92%. 
4e: Yield 70%. m.p. 145-47°C. IR (KBr): 1670 
(C=O), 3285 (NH) cm
−1
; 
1
H NMR (300 MHz, 
CDCl3): δ 2.2 (s, 3H, CH3), 2.3 (s, 3H, CH3), 3.3 (d, 
2H, CH2), 3.8 (s, 3H, OCH3), 4.5 (t, 1H, COCHS), 5.5 
(s, 1H, N-CH-Ar), 7.0-7.8 (m, 7H, Ar-H), 9.1 (bs, 1H, 
NH, D2O exchangeable); ESI-MS: m/z 480 [M+H]
+
. 
Anal. Calcd. for C23H21N5O5S: C, 57.62; H, 4.38; N, 
14.61. Found: C, 57.60; H, 4.35; N, 14.64%. 
4f: Yield 70%, 165-67°C. IR (KBr): 1675 (C=O), 
3310 (NH) cm
−1
; 
1
H NMR (300 MHz, CDCl3): δ 2.1 
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(s, 3H, CH3), 2.2 (s, 3H, CH3), 3.2 (d, 2H, CH2), 4.4 
(t, 1H, COCHS), 5.4 (s, 1H, N-CH-Ar), 7.0-7.7  
(m, 8H, Ar-H), 9.0 (bs, 1H, NH, D2O exchangeable); 
ESI-MS: m/z 439 [M+H]
+
. Anal. Calcd. for 
C22H19N4O2SCl: C, 60.27; H, 4.33; N, 12.78. Found: 
C, 60.29; H, 4.35; N, 12.80%. 
4g: Yield 70%. m.p. 160-62°C. IR (KBr): 1670 
(C=O), 3300 (NH) cm
−1
; 
1
H NMR (300 MHz, 
CDCl3): δ 2.2 (s, 3H, CH3), 2.3 (s, 3H, CH3), 3.2 (d, 
2H, CH2), 4.2 (t, 1H, COCHS), 5.5 (s, 1H, N-CH-Ar), 
7.0-7.7 (m, 8H, Ar-H), 9.2 (bs, 1H, NH, D2O 
exchangeable); ESI-MS: m/z 439 [M+H]
+
. Anal. 
Calcd. for C22H19N4O2SCl: C, 60.27; H, 4.33; N, 
12.78. Found: C, 60.24; H, 4.30; N, 12.76%. 
4h: Yield 75%. m.p. 155-57°C. IR (KBr): 1675 
(C=O), 3290 (NH) cm
−1
; 
1
H NMR (300 MHz, 
CDCl3): δ 2.2 (s, 3H, CH3), 2.3 (s, 3H, CH3), 2.5 (s, 
3H, Ar-CH3), 3.3 (d, 2H, CH2), 4.4 (t, 1H, COCHS), 
5.5 (s, 1H, N-CH-Ar), 7.0-7.5 (m, 7H, Ar-H), 9.0 (bs, 
1H, NH, D2O exchangeable); ESI-MS: m/z 464 
[M+H]
+
. Anal. Calcd. for C23H22N4O2S: C, 66.02; H, 
5.26; N, 13.39. Found: C, 66.05; H, 5.28; N, 13.37%. 
4i: Yield 65%. m.p. 170-72°C. IR (KBr): 1670 
(C=O), 3295 (NH) cm
−1
; 
1
H NMR (300 MHz, 
CDCl3): δ 2.1 (s, 3H, CH3), 2.2 (s, 3H, CH3), 3.3 (d, 
2H, CH2), 3.8 (s, 3H, OCH3), 4.5 (t, 1H, COCHS), 5.6 
(s, 1H, N-CH-Ar), 7.0-7.5 (m, 5H, Ar-H), 9.0 (bs, 1H, 
NH, D2O exchangeable), 9.8 (bs, 1H, OH, D2O 
exchangeable); ESI-MS: m/z 519 [M+H]
+
. Anal. 
Calcd. for C23H20N4O4SCl3: C, 53.28; H, 3.86; N, 
10.81. Found: C, 53.24; H, 3.89; N, 10.83%. 
4j: Yield 65%. m.p. 176-78°C. IR (KBr): 1675 
(C=O), 3300 (NH) cm
−1
; 
1
H NMR (300 MHz, 
CDCl3): δ 2.2 (s, 3H, CH3), 2.3 (s, 3H, CH3), 3.3 (d, 
2H, CH2), 4.0 (s, 2H, OCH2O), 4.5 (t, 1H, COCHS), 
5.5 (s, 1H, N-CH-Ar), 7.0-7.6 (m, 5H, Ar-H), 9.3 (bs, 
1H, NH, D2O exchangeable); ESI-MS: m/z 517 
[M+H]
+
. Anal. Calcd. for C23H18N4O4SCl2: C, 53.48; 
H, 3.48; N, 10.85. Found: C, 53.45; H, 3.45; N, 
10.88%. 
 
Anti-inflammatory activity 
The albino rats weighing between 150 and 180 g 
were used for anti-inflammatory activity by 
Carragenon induced rat wind paw method. They were 
kept in animal house under standard conditions of 
light and temperature with free access to food and 
water. The rats were randomly divided into 12 groups, 
with six animals in each group. One group was kept 
as control, another group received the standard drug 
Indomethacin (at a dose of 10 mg/kg B. W. P.O) the 
rest were treated with test compounds which were 
dissolved in 0.05 mL solution of DMSO. Edama was 
induced in all groups of animals by subplanatar 
injection of Carragenon solution in normal saline  
of left hind paw under light ether anaesthesia, 1 h 
after oral administration of test compounds. The paw 
volume was recorded by plethysmograph at 1,2,3 and 
4 h. after administration of DMSO. The edema was 
expressed as an increase in the volume of paw, and 
the % of edema inhibition for each rat and each group 
was calculated as follows: 
%Inhibition =
(vt - vo) control - (vt - vo) test compound x 100
(vt - vo) control)  
Where vt = volume of edema at specific time 
v○ = volume of edema at zero time interval 
 
Analgesic activity 
Albino rats weighing 150-180 g were used for 
evaluation of analgesic activity by Hot Plate method. 
They were kept in animal house under standard 
conditions of light and temperature with free access to 
food and water. The animals were randomly divided 
into 12 groups, with six animals in each group. One 
group was kept as a control, and another group 
received the standard drug Indomethacin (at a dose of 
10mg/kg B.W. P. O), and remaining groups were 
treated with test compounds (10mg/kg b. w.) orally. 
The paws of rats are very sensitive to heat at a 
temperature which does not damage the skin. The 
responses are jumping, withdrawal of the paws and 
licking of the paws. The animals are placed on the hot 
plate and observations were recorded at the time 
interval of 0, 1, and 2 h. The recorded values were  
the average of six administrations  S.E. and the 
percentage inhibition of the comparison with the basal 
values. 
 
Conclusion 
In conclusion, a simple and efficient protocol for 
the synthesis of isoxazolyl thiazolyl benzimidazoles 
has been described. The title compounds have been 
evaluated for their anti-inflammatory and analgesic 
activities. Some of the newly synthesized compounds 
exhibited remarkable activity in comparison with 
reference drugs. 
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